Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Related Posts
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im[...]
Chandrasekhar A, Yang HC, Demir T, Yeldandi A, Kurihara C, Tomic R, Gao R, Goldman JW, Nadig S, Chae YK, Bharat A. Multiorgan transplant for[...]
Fu X, Ma J, Ma F, Guo S, Wang X, Li Y, Tang Y, Qi J, Zhang W, Ye L. MISP-mediated enhancement of pancreatic cancer[...]